Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ascentawits Pharmaceuticals Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a different examiner and art unit, while HAVLIN, ROBERT H handles 1 pending matter.
The assignments create separate prosecution contexts within the same technology area. Practitioners should coordinate scientific positions across the portfolio but develop response arguments that reflect each examiner’s treatment of the pending claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| KOVACH, KARA NICOLE | 1 | 85.7% | +100.0% |
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
| SAWYER, JENNIFER C | 1 | 68.4% | -8.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686957 | PARP INHIBITOR-RESISTANT PATIENT TREATED WITH TH-302 | HAVLIN, ROBERT H | — |
| 18547733 | PRIMER-PROBE COMPOSITION, KIT, AND DETECTION METHOD | KOVACH, KARA NICOLE | — |
| 18043610 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686957 | PARP INHIBITOR-RESISTANT PATIENT TREATED WITH TH-302 | HAVLIN, ROBERT H | — |
| 18547733 | PRIMER-PROBE COMPOSITION, KIT, AND DETECTION METHOD | KOVACH, KARA NICOLE | — |
| 18043610 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1681 | 1 |
| 1678 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686957 | PARP INHIBITOR-RESISTANT PATIENT TREATED WITH TH-302 | HAVLIN, ROBERT H | 1626 | §101§102§112DP | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18547733 | PRIMER-PROBE COMPOSITION, KIT, AND DETECTION METHOD | KOVACH, KARA NICOLE | 1681 | §101§103§112 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18043610 | AKR1C3 DETECTION METHOD, AND DIAGNOSTIC KIT FOR DETECTING AKR1C3 AND USE THEREOF | IVICH, FERNANDO NMN | 1678 | §103§112 | Final Rejection | — | Pending | Mar 01, 2023 |
| 18003402 | A DEUTERATED COMPOUND, AND PREPARATION METHOD AND USE THEREOF | SAWYER, JENNIFER C | 1691 | §112 | Final Rejection | 29d | Pending | Dec 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAscentawits Pharmaceuticals Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Robert H Havlin has the most, with 1 of Ascentawits Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
